MedTrace Logo

A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)

NCT05540860 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2025-11-12

No results posted yet for this study

Summary

The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a randomized, double-blind, placebo-controlled part A, followed by an open-label part B.

Conditions

Interventions

DRUG

Sevasemten Dose 1

Sevasemten is administered orally once per day

DRUG

Sevasemten Dose 2

Sevasemten is administered orally once per day

DRUG

Sevasemten Dose 3

Sevasemten is administered orally once per day

DRUG

Sevasemten Dose 4

Sevasemten is administered orally once per day

DRUG

Sevasemten Dose 5

Sevasemten is administered orally once per day

DRUG

Placebo

Placebo is administered orally once per day

Sponsors & Collaborators

  • Edgewise Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
4 Years
Max Age
9 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-24
Primary Completion
2027-01-31
Completion
2027-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05540860 on ClinicalTrials.gov